Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth

Clinical Cancer Research

Volumn 19, Issue 8, 2013, Pages 2096-2106

  Leone, Emanuela ^a   Morelli, Eugenio ^a   Di Martino, Maria T ^a   Amodio, Nicola ^a   Foresta, Umberto ^a   Gullà, Annamaria ^a   Rossi, Marco ^a   Neri, Antonino ^b   Giordano, Antonio ^c,f   Munshi, Nikhil C ^d,e   Anderson, Kenneth C ^d   Tagliaferri, Pierosandro ^a   Tassone, Pierfrancesco ^a,f  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Temple University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BTG2 PROTEIN; MICRORNA 21; MICRORNA 21 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RHO B FACTOR; RHO FACTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMEDIATE-EARLY PROTEINS; MALE; MICE; MICE, SCID; MICRORNAS; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOB GTP-BINDING PROTEIN; RNA, ANTISENSE; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877100047     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3325     Document Type: Article

References (50)

1. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011;6:249-74.
2. Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011;8:479-91.
3. Tassone P, Neri P, Burger R, Di Martino MT, Leone E, Amodio N, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012;12:814-22.
4. Rossi M, Di Martino MT, Morelli E, Leotta M, Rizzo A, Grimaldi A, et al. Molecular targets for the treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:757-67.
5. Hideshima T, Anderson KC. Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol 2011;94:344-54.
6. Podar K, Anderson KC. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Curr Cancer Drug Targets 2011;11:1005-24.
7. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009;23:10-24.
8. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012;12:335-48.
9. Klein B, Seckinger A, Moehler T, Hose D. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res 2011;183:39-86.
10. Tassone P, Tagliaferri P, Rossi M, Gaspari M, Terracciano R, Venuta S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management? Eur J Cancer 2006;42:1530-8. (Pubitemid 44118767)
11. Benetatos L, Vartholomatos G. Deregulated microRNAs in multiple myeloma. Cancer 2012;118:878-87.
12. Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012;12:823-37.
13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
14. Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle 2008;7:2485-92.
15. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
16. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 2009;10:704-14.
17. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010;9:775-89.
18. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene 2008;27(Suppl 2):S52-7
19. Di Martino MT, Gullà A, Gallo Cantafio ME, Lionetti M, Leone E, Amodio N, et al. In vitro and in vivo activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55.
20. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, Gullà A, et al. Promises and challenges of microRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:838-46.
21. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70.
22. Amodio N, Leotta M, Bellizzi D, Di Martino MT, D'Aquila P, Lionetti M, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012;3:1246-58.
23. Amodio N, Di Martino MT, Foresta U, Leone E, Lionetti M, Leotta M, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis 2012;3:e436.
24. Rossi M, Pitari MR, Amodio N, Di Martino MT, Conforti F, Leone E, et al. miR-29b negatively redulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2012 Dec18. [Epub ahead of print].
25. Tassone P, Tagliaferri P. Editorial: new approaches in the treatment of multiple myeloma: from target-based agents to the new era of micro-RNAs. Curr Cancer Drug Targets 2012;12:741-2.
26. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2011;10:1224-32.
27. Rosato P, Anastasiadou E, Garg N, Lenze D, Boccellato F, Vincenti S, et al. Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2. Leukemia 2012;26:2343-52.
28. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010;467:86-90.
29. Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, et al. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70:4528-38.
30. Shi L, Chen J, Yang J, Pan T, Zhang S, Wang Z. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 2010;1352:255-64.
31. Shi GH, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, et al. Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 2010;31:867-73.
32. Corthals SL, Sun SM, Kuiper R, de Knegt Y, Broyl A, van der Holt B, et al. MicroRNA signatures characterize multiple myeloma patients. Leukemia 2011;25:1784-9.
33. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermüller J, Kretzschmar AK, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007;110:1330-3. (Pubitemid 47281433)
34. Xiong Q, Zhong Q, Zhang J, Yang M, Li C, Zheng P, et al. Identification of novel miR-21 target proteins in multiple myeloma cells by quantitative proteomics. J Proteome Res 2012;11:2078-90.
35. Wang X, Li C, Ju S, Wang Y, Wang H, Zhong R. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation. Leuk Lymphoma 2011;52:1991-8.
36. Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res 2009;15:7144-52.
37. Ditzel Santos D, HoAW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, et al. Establishment of BCWM.1 cell line of Waldenstrom's macroglobulinemia with productive in vivo engrafment in SCID-hu mice. Exp Hematol 2007;35:1366-75.
38. Correale P, Tagliaferri P, Fioravanti A, Del Vecchio MT, Remondo C, Montagnani F, et al. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial). Clin Cancer Res 2008;14:4192-9.
39. Calimeri T, Battista E, Conforti F, Neri P, Di Martino MT, Rossi M, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011;25:707-11.
40. Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008;143:520-31.
41. Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Catley LP, et al. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol 2006;134:37-44. (Pubitemid 43830025)
42. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, et al. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 2009;8:648-53.
43. Wang S, Cheng Z, Yang X, Deng K, Cao Y, Chen H, et al. Effect of wild type PTENgene on proliferation and invasion of multiple myeloma. Int J Hematol 2010;92:83-94.
44. Winkler GS. The mammalian anti-proliferative BTG/Tob protein family. J Cell Physiol 2010;222:66-72.
45. Karlsson R, Pedersen ED, Wang Z, Brakebusch C. Rho GTPase function in tumorigenesis. Biochim Biophys Acta 2009;1796:91-8.
46. Tassone P, Forciniti S, Galea E, Savino R, Turco MC, Iacopino P, et al. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and dexamethasone. Cell Death Differ 2000;7:327-8. (Pubitemid 30192981)
47. Tassone P, Galea E, Forciniti S, Tagliaferri P, Venuta S. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 2002;21:867-73.
48. Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 2012;32:190-5.
49. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004;30:193-204.
50. Sayed D, He M, Hong C, Gao S, Rane S, Yang Z, et al. MicroRNA-21 is a downstream effector of AKT that mediates its antiapoptotic effects via suppression of Fas ligand. J Biol Chem 2010;285:20281-90.